GLP-2 Receptor Agonism & Intestinal Mucosal Growth
Teduglutide — Glucagon-Like Peptide-2 Analog
Teduglutide (GLP-2 T) is a synthetic analog of glucagon-like peptide-2 (GLP-2), an intestinotrophic hormone produced by L-cells of the distal small intestine and colon. While GLP-1 and GLP-2 are both derived from the same proglucagon gene, they have entirely distinct receptor targets and physiological roles: GLP-2 acts specifically on the gastrointestinal tract to promote intestinal mucosal growth, enhance nutrient absorption, and maintain intestinal barrier integrity.
Teduglutide is FDA-approved under the brand name Gattex® for the treatment of Short Bowel Syndrome (SBS) in adults and pediatric patients, making it one of the few research peptides in this catalog with full regulatory approval and extensive human clinical data.
Teduglutide is a 33-amino-acid peptide analog of native GLP-2, with a single amino acid substitution: Ala² → Gly. This substitution prevents DPP-IV cleavage at the His¹-Ala² bond, extending the half-life from approximately 7 minutes (native GLP-2) to approximately 1.3 hours (teduglutide). The molecular weight is 3,752.13 Daltons.
Teduglutide acts as a potent agonist of the GLP-2 receptor (GLP-2R), a G-protein coupled receptor expressed primarily on subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells in the gastrointestinal tract. GLP-2R activation stimulates the Gαs/adenylyl cyclase/cAMP pathway, triggering downstream effects that include stimulation of intestinal crypt cell proliferation, inhibition of enterocyte apoptosis, and increased intestinal blood flow.
The net effect is an increase in villus height and crypt depth — the structural determinants of intestinal absorptive capacity. Teduglutide also enhances intestinal barrier function by upregulating tight junction proteins, and may modulate gastric emptying and acid secretion through enteric nervous system effects.
GLP-2 T (Teduglutide) is a stabilized analog of GLP-2, a hormone your gut produces that acts as a growth signal specifically for the intestinal lining. It's been FDA-approved since 2012 under the brand name Gattex® for short bowel syndrome — a condition where patients can't absorb enough nutrients because too much of their small intestine has been removed or is non-functional.
GLP-2 T works by activating the GLP-2 receptor on intestinal cells, which triggers a cascade that increases the height of intestinal villi (the finger-like projections that absorb nutrients), stimulates new cell growth in the gut lining, and reduces intestinal cell death. The net effect is a larger, more functional absorptive surface area. In clinical trials, it significantly reduced the need for IV nutrition in short bowel syndrome patients.
The gut lining is one of the fastest-renewing tissues in the body, and GLP-2 is one of its primary growth regulators. Beyond short bowel syndrome, researchers are studying GLP-2 analogs for inflammatory bowel disease, gut barrier function, and the gut-brain axis. The FDA approval of teduglutide provides a robust clinical foundation for this research area.
GLP-2 T (Teduglutide) is FDA-approved for short bowel syndrome, giving it one of the strongest clinical validation profiles in this catalog. The research-grade lyophilized powder supplied by Purgo Labs is for laboratory use only and differs from the clinical formulation. Its intestinotrophic mechanism makes it a key tool for gut biology research.
Activates GLP-2R on subepithelial myofibroblasts and enteric neurons, stimulating cAMP-mediated intestinal mucosal growth signals.
Stimulates crypt cell proliferation and inhibits enterocyte apoptosis, increasing villus height and absorptive surface area.
Upregulates tight junction proteins (claudin, occludin), strengthening the intestinal epithelial barrier against luminal antigens.
Activates β-catenin signaling pathway in intestinal epithelial cells, contributing to proliferative and survival effects.
Metabolic Research
≥99% purity · Third-party tested
Use code Health for 15% off
Fast FedEx shipping · 60-day guarantee
| Peptide Class | GLP-2 analog (33 amino acids) |
| Molecular Weight | 3,752.13 Da |
| FDA Approval | Gattex® — Short Bowel Syndrome |
| Receptor Target | GLP-2 receptor (GLP-2R) |
| Key Modification | Ala²→Gly substitution (DPP-IV resistance) |
| Available Sizes | 5mg vials |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
View full legal status guide →
Purgo Labs offers GLP-2 T with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.
Purchase GLP-2 T at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.
